These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37129897)

  • 1. Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
    Abe M; Yamaguchi T; Fujita Y; Nishimura T; Kitagawa K; Inui N; Hirano K; Sakata Y; Iihara H; Shibuya Y; Suzuki K; Shibata K; Hori K; Daga H; Nakayama T; Sakata Y; Takahashi TY; Zenda S; Hashimoto H
    JAMA Netw Open; 2023 May; 6(5):e2310894. PubMed ID: 37129897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
    Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
    Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
    Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
    BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.
    Hashimoto H; Abe M; Yanai T; Yamaguchi T; Zenda S; Uchitomi Y; Fukuda H; Mori M; Iwasa S; Yamamoto N; Ohe Y
    Jpn J Clin Oncol; 2018 Oct; 48(10):950-952. PubMed ID: 30124989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial.
    Ostwal V; Ramaswamy A; Mandavkar S; Bhargava P; Naughane D; Sunn SF; Srinivas S; Kapoor A; Mishra BK; Gupta A; Sansar B; Pal V; Pandey A; Bonda A; Siripurapu I; Muddu VK; Kannan S; Chaugule D; Patil R; Parulekar M; Dhanawat A; Trikha M; Ghosh J; Noronha V; Menon N; Patil V; Prabhash K; Olver I
    JAMA Netw Open; 2024 Aug; 7(8):e2426076. PubMed ID: 39106066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
    Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
    Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
    Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).
    Zhao Y; Yang Y; Gao F; Hu C; Zhong D; Lu M; Yuan Z; Zhao J; Miao J; Li Y; Zhu J; Wang C; Han J; Zhao Y; Huang Y; Zhang L
    EClinicalMedicine; 2023 Jan; 55():101771. PubMed ID: 36712888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
    Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
    Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Bajpai J; Kapu V; Rath S; Kumar S; Sekar A; Patil P; Siddiqui A; Anne S; Pawar A; Srinivas S; Bhargava P; Gulia S; Noronha V; Joshi A; Prabhash K; Banavali S; Sarin R; Badwe R; Gupta S
    Lancet Oncol; 2024 Feb; 25(2):246-254. PubMed ID: 38224701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
    Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
    BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
    Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
    Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.